A Randomized, Double-blind, Placebo-controlled Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of SAR279356 in Patients Hospitalized in Intensive Care Unit and on Mechanical Ventilation

Brief Summary

Primary Objective:

- To determine the pharmacokinetics (PK) of a single intravenous (IV) dose of SAR279356 administered to intensive care unit (ICU) patients on mechanical ventilation

Secondary Objectives:

To determine the safety and tolerability of SAR279356

To evaluate the pharmacodynamics (PD) and immunogenicity of SAR279356

Exploratory efficacy of SAR279356 on prevention of bacterial infections

Detailed Description

Total study duration (from screening to last follow-up visit) is 91 days break down as follows: